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Abstract
Global analysis of gene expression by DNA microarrays is nowadays a widely used tool, especially relevant for
cancer research. It helps the understanding of complex biology of cancer tissue, allows identification of novel
molecular markers, reveals previously unknown molecular subtypes of cancer that differ by clinical features like
drug susceptibility or general prognosis. Our aim was to compare gene expression profiles in breast cancer that
develop against a background of inherited predisposing mutations versus sporadic breast cancer. In this preli-
minary study we analysed seven hereditary, BRCA1 mutation-linked breast cancer tissues and seven sporadic ca-
ses that were carefully matched by histopathology and ER status. Additionally, we analysed 6 samples of normal
breast tissue. We found that while the difference in gene expression profiles between tumour tissue and normal
breast can be easily recognized by unsupervised algorithms, the difference between those two types of tumours
is more discrete. However, by supervised methods of data analysis, we were able to select a set of genes that
may differentiate between hereditary and sporadic tumours. The most significant difference concerns genes that
code for proteins engaged in regulation of transcription, cellular metabolism, signalling, proliferation and cell
death. Microarray results for chosen genes (TOB1, SEPHS2) were validated by real-time RT-PCR.
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Introduction
DNA microarrays have been recently widely em-
ployed in studies on breast cancer encompassing re-
search on breast cancer cell lines and resected tumo-
ur tissues. Two directions of these studies seem to be
especially spectacular and promising: the studies of
the Norwegian/Stanford group that led to the recogni-
tion of several distinct molecular classes of breast can-
cers [1, 2] and the studies of a group at the Nether-
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lands Cancer Institute, which brought identification of
a 70-gene prognostic profile for patients with node-
-negative breast cancer [3, 4]. The results of those stu-
dies indicate that gene expression analysis by DNA mi-
croarrays may help the understanding of the molecu-
lar background underlying development and
progression of breast cancer as well as providing a cli-
nically useful tool for more personalized treatment [re-
viewed in: 5]. It seems clear that a multi-gene appro-
ach will prove more useful and informative than cur-
rently used analysis of single markers.
Since the identification of two major predisposing
genes, BRCA1 and BRCA2, and broad application of
genetic testing, significant numbers of mutation carriers
have been identified worldwide among breast cancer
patients. This allowed further studies in order to estima-
te clinical features of those specific breast cancer ca-
ses. Some indications are accumulating that mutation-
-linked breast cancer may be a clinically distinct entity
from the majority of malignant breast tumours. Among
the characteristics of BRCA1 tumours are: earlier age
of manifestation, high tumour grade, low oestrogen re-
ceptor content and elevated lymphocyte infiltration. In
addition, these cases are often characterized by high
proliferative activity, resulting in tumours with pushing
margins and high mitotic index [6-12]. The data con-
cerning survival in BRCA1 mutation carriers are confu-
sing. There are intriguing observations that despite ad-
verse prognostic indications, patients with BRCA1 mu-
tations have survival rates similar to or even better than
patients with sporadic breast cancer [13-15, own unpu-
blished data]. The long-term aim of our study is an at-
tempt to elucidate the molecular basis underlying de-
scribed discrepancies by comparing gene expression
profiles of BRCA1-associated hereditary breast cancer
and sporadic breast cancer cases. The first attempt to
compare hereditary versus sporadic breast cancers by
DNA microarray analysis was published by Hedenfalk
et al., who used cDNA microarrays containing 6512
cDNA clones [16]. In our study we used HG U133 Plus
2.0 Gene Chip (Affymetrix), allowing detection of over
47,000 transcripts. We also attempted to make a mo-
re careful selection of tumour specimens, which were
chosen exclusively from among ER(-) cases. Our gro-
up of tumours was also more uniform according to hi-
stopathology; only ductal carcinomas and medullary
carcinomas, all grade 3, were analysed.
Materials and methods
Tissue samples. Frozen surgical specimens of bre-
ast cancer and adjacent normal breast tissue were ob-
tained from the Pomeranian Medical Academy in
Szczecin. Only tissues from patients without preceding
chemotherapy were used for microarray experiments.
For this initial study we chose seven cancer tissues from
women with germline mutation in the BRCA1 gene and
seven samples of sporadic breast cancer. Three cases
had mutation C61G in exon 5, one at 4153delA in
exon 11, and three harboured the 5382insC mutation
in exon 20. Sporadic cases were obtained from wo-
men without a family history of breast/ovarian cancer,
in which, additionally, the three most common BRCA1
mutations in Poland were excluded by genetic tests.
Eight cases were diagnosed as grade 3 medullary or
atypical medullary carcinoma, and 5 cases were gra-
de 3 ductal carcinomas. All tumours were ER negati-
ve (immunohistochemistry on paraffin-embedded ma-
terial). The percentage of cancer cells within tumour
specimens was estimated by a pathologist; in the ma-
jority of samples it ranged from 70% to 90%, while in
3 samples it was approx. 50%. In addition, we analy-
sed six samples of unchanged glandular tissue surro-
unding the tumour and obtained during mastectomy.
The lack of tumour samples from BRCA2 mutation car-
riers in our study reflects the specificity of the mutatio-
nal spectrum in BRCA genes in Central-Eastern Euro-
pe, where BRCA2 mutations are very rare (it was esti-
mated by sequencing that BRCA2 mutations account
for only about 5% of all BRCA1 and BRCA2 mutations
found in Polish families with a strong familial history of
breast/ovarian cancer [17]). In total we analysed 14
tumour samples and 6 normal breast samples. 
RNA isolation. 20-40 mg of frozen tissue was pla-
ced in a lysing solution (4M guanidine thiocyanate, 25
mM sodium citrate, 0.5% sodium N-laurylsarcosinate,
0.1M β-mercaptoethanol) and homogenized with Ly-
sing Matrix D in a FastPrep instrument (QBioGene).
Total RNA was extracted from the supernatant accor-
ding to [18]. RNA cleanup and simultaneous on-co-
lumn digestion of DNA traces with DNAse I (Qiagen)
was done using the RNeasy Mini Kit (Qiagen), accor-
ding to the manufacturer’s instructions. RNA quantity
was estimated with the ND-1000 Spectrophotometer
(NanoDrop Technologies). RNA quality was controlled
by microcapillary electrophoresis measurements in the
Agilent 2100 Bioanalyzer using the RNA 6000 Nano
LabChip Kit and analysed with RNA Integrity Number
software (Agilent). 
Oligonucleotide microarrays. We used HG U133 Plus
2.0 Gene Chip oligonucleotide arrays (Affymetrix). The
hybridization target was prepared according to recom-
mendations of microarray manufacturer. Briefly: 8 µg of
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total RNA was used for synthesis of double stranded
cDNA, half volume of cDNA was used for synthesis of
biotynylated cRNA with the BioArray High Yield RNA
Transcript Labeling Kit (Enzo Diagnostics). Both cDNA
and cRNA were purified with Gene Chip Sample Cle-
anup Module (Affymetrix). 16g of cRNA was fragmented
and hybridized to the microarray for 16h at 45°C. After
washing and staining microarrays were scanned with Ge-
neChip Scanner 3000 (Affymetrix). 
Statistical analysis of microarray data. Data were ob-
tained using GCOS 1.2 software (Affymetrix). The pre-
processing was performed by Robust Multi-Array Analy-
sis (RMA). Hierarchical clustering, Principal Component
Analysis (PCA) and supervised comparisons were car-
ried out using GeneSpring 7.2 software (Silicon Gene-
tics). For selection of genes differentially expressed be-
tween breast cancer and normal breast tissue we used
the parametric Welch test. False Discovery Rate was es-
timated by Benjamini-Hochberg algorithm. For selection
of genes differentially expressed between hereditary and
sporadic breast cancer we used the  Bioconductor lim-
ma package, based on linear models with empirical Bay-
esian approach. This method provides stable results even
when the number of analysed arrays is small. 
Quantitative RT-PCR. Quantitative RT-PCR analysis
was performed using the ABI 7700 Sequence Detec-
tion System and dedicated software (Applied Biosys-
tems). The reactions were performed using the Maste-
rAmp Real-Time RT-PCR Kit (Epicentre), according to
the manufacturer’s recommendations. Primers for the
SYBR Green system were designed using Primer3 on-
line software (http://frodo.wi.mit.edu/cgi-bin/prime-
r3/primer3_www.cgi). All results were normalised to
the expression of the reference gene, eukaryotic trans-
lation initiation factor 4 gamma 2 (EIF4G2), which ap-
peared to be equally transcribed in all tissues analy-
sed by microarrays. Primer specificity was verified by
sequencing of selected RT-PCR products for each ge-
ne. Sequences of the PCR primer pairs used for each
gene are shown in Table 1.
Results
Unsupervised analysis of obtained data set. We per-
formed Principal Component Analysis (PCA) to deter-
mine the major sources of variability in our data (Fig.
1). PCA is an unsupervised algorithm, which, if perfor-
med ‘on conditions’, is able to detect intrinsic simila-
rities and differences in the gene expression profiles of
analysed samples. Results may be graphically presen-
ted and the distances between the dots visualize the le-
vel of similarity/dissimilarity between particular sam-
ples. It can be seen that the difference in gene expres-
sion profile between breast cancer tissue and normal
breast tissue is large and is easily recognized by that
unsupervised algorithm (normal-tumour difference was
responsible for the sample subdivision by the first com-
ponent, which accounted for 24.06% of total varian-
ce). Using a supervised method of data analysis we fo-
Table 1. Primers used for quantitative RT-PCR
Gene Oligonucleotide Sequence product size
SEPHS2 forward primer 5`-GGAAAGGAGGACCTGCAACCA-3` 154bp
reverse primer 5`-ACCAGGAATCTGCCGCAAAAG-3`
TOB1 forward primer 5`-ttgtttctacgacatggtattgcattta-3` 182bp
reverse primer 5`-caagtattcgtacattttaattccaccact-3`
EIFG2 forward primer 5`-GCAAGGCTTTGTTCCAGGTGA-3` 100bp
reverse primer 5`-AGGCTTTGGCTGGTTCTTTAGTCA-3`
Fig. 1. Principal component analysis (PCA) performed on the who-
le set of 20 samples. The tumor (red and blue) vs. normal (green)
difference is clearly visible within the 1st component, which accoun-
ted for 24.06% of total variance. PCA is unable to reveal a diffe-
rence between hereditary (red) and sporadic tumors (blue)
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und that this precise separation of cancer versus nor-
mal tissues in PCA may be ascribed to the differential
expression of 8,063 genes (Welch test, Benjamini-
-Hochberg correction for multiple comparisons,
FDR<0.05). In contrast, the difference between here-
ditary and sporadic breast cancer samples cannot be
recognized by PCA, suggesting that the difference in
gene expression profile between those two types of bre-
ast cancer is not very powerful. Samples obtained from
normal glandular breast tissue clustered closely toge-
ther, while tumours were much more dispersed. By
unsupervised analysis we were unable to disclose any
differences between hereditary and sporadic tumours;
they were not visible also when only cancer samples
were subjected to decomposition into principal com-
ponents (data not shown). 
Genes differentiating between hereditary and spo-
radic breast tumours. As the unsupervised method sho-
wed that the distance between hereditary and spora-
dic tumours is not large and taking into account the
limited number of samples in our analysis, we chose
a supervised algorithm with a good balance of sensi-
tivity and specificity of analysis. We used the limma
package [19], a Bayesian method based on linear mo-
delling with moderated t-statistic.
We selected 100 genes best differentiating betwe-
en the two analysed groups, ranked according to the
statistical power of the expression change (Table 2.).
Four times more probe sets were down-regulated in
hereditary tumours (78 probesets) in comparison to
up-regulated transcripts (22 probe sets). Down-regu-
lated genes showed an average decrease of 1.35 to
5-fold, up-regulated genes were changed by a factor
of 1.2-7.8. Among the first hundred genes selected by
limma the most prominent classes consisted of genes
connected with regulation of transcription (19 genes),
metabolism (12 genes), protein synthesis and degra-
dation (10 genes), cellular signalling (8 genes), cell
proliferation and death (6 genes) and DNA and RNA
replication and processing (5 genes). 
Figure 2 shows that use of a set of 100 genes for
hierarchical clustering results in almost perfect classi-
fication of hereditary and sporadic tumour samples.
Only one sporadic sample falls into the branch of he-
reditary cases. 
Within a set of 100 genes selected in our study, we
found genes coding for proteins known to be interac-
ting with the BRCA1 pathway, such as Fanconi Ane-
mia complementation group A gene (FANCA, incre-
ased 2-fold) and XRCC5 (50% decrease), which are
both engaged in double-strand break repair. FANCA
protein is a component of the multi-subunit FA com-
plex which takes part in sensing and/or regulation of
the DNA damage response. The FA complex activates
FANCD2 protein which is further targeted to the
BRCA1 nuclear loci. Inactivation of the FA/BRCA pa-
thway leads to chromosomal instability, due to impa-
ired DNA repair [20]. DNA repair protein XRCC5 (80
kDa Ku autoantigen) is the DNA-binding component
of the DNA-dependent protein kinase, and functions
together with the DNA ligase IV-XRCC4 complex in the
repair of DNA double-strand break by non-homolo-
gous end joining [21]. 
The TOB1 gene (transducer of ERBB2 gene, decre-
ased in hereditary tumours) encodes a member of the
tob/btg1 family of anti-proliferative proteins that have
the potential to regulate cell growth, and is probably
engaged in several human tumours (breast, lung, thy-
roid) [22-25]. This protein inhibits T cell proliferation
and transcription of cytokines and cyclins. This is the
only gene from Hedenfalk’s list [15] that appears wi-
thin the first 100 genes selected by limma.
Another interesting gene is selenophosphate syn-
thetase 2 (SEPHS2, decreased in hereditary tumours).
This protein encodes an enzyme that synthesizes sele-
nophosphate from selenide and ATP. Selenophospha-
te is the selenium donor used to synthesize selenocy-
steine, which is co-translationally incorporated into se-
lenoproteins at in-frame UGA codons. This protein itself
contains a selenocysteine residue in its predicted acti-
ve site. It has been proposed that the effects of sele-
nium in preventing cancer and neurological disorders
may be mediated by selenium-binding proteins [26].
The most prominent among genes up-regulated in
hereditary carcinomas is a group of immune respon-
se genes (5 genes). On the contrary, no immunologi-
cal genes are found in the list of down-regulated ge-
nes. This may reflect a common feature of BRCA1-lin-
ked breast cancer, i.e. the inflammatory state and
lymphocyte infiltrate of a tumour. It is especially stri-
king as all our tumour samples were inspected by a
pathologist, and only pieces of tumour mass without
a visible inflammatory state were taken for microarray
experiments. Thus we conclude that this immunologi-
cal imprint must be very prominent in BRCA1(+) bre-
ast cancer.
Validation of microarray results by Q RT-PCR. We
selected TOB1 and SEPHS2 genes (see Table 1) for
further analysis by quantitative RT-PCR. We examined
Hereditary Cancer in Clinical Practice 2006; 4(1)32
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Table 2. Genes differentiating between hereditary, BRCA1-positive breast cancers and sporadic tumours, selected by limma. Genes are
ordered according to the fold change value and grouped into functional classes (according to Gene Ontology annotation,
http://www.geneontology.org/)




Cell proliferation and death
202704_at TOB1 transducer of ERBB2, 1 0.364 75
243031_at RTN4 Reticulon 4 0.421 71
1556049_at RTN4 reticulon 4 0.506 46
215070_x_at RABGAP1 RAB GTPase activating protein 1 0.731 97
Cell signalling
1553986_at RASEF RAS and EF-hand domain containing 0.25 49
244181_at PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) 0.381 80
238176_at RAPGEF2 Rap guanine nucleotide exchange factor (GEF) 2 0.461 58
229261_at SOS1 Son of sevenless homolog 1 (Drosophila) 0.565 92
215992_s_at RAPGEF2 Rap guanine nucleotide exchange factor (GEF) 2 0.583 90
207822_at FGFR1 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, 0.704 82
Pfeiffer syndrome)
DNA and RNA
233007_at XRCC5 X-ray repair complementing defective repair 0.667 22
in Chinese hamster cells 5 (double-strand-break rejoining; 
Ku autoantigen, 80kDa)
230651_at THOC2 THO complex 2 0.414 45
243908_at ZNF638 Zinc finger protein 638 0.531 17
218356_at FTSJ2 FtsJ homolog 2 (E. coli) 0.699 57
Metabolism
239545_at CAS1 O-acetyltransferase 0.331 26
238563_at TPRT Trans-prenyltransferase 0.351 14
215316_at HIBADH 3-hydroxyisobutyrate dehydrogenase 0.539 30
200961_at SEPHS2 selenophosphate synthetase 2 0.576 72
202282_at HADH2 hydroxyacyl-Coenzyme A dehydrogenase, type II 0.585 2
238813_at ALAS2 Aminolevulinate, delta-, synthase 2 0.607 7
(sideroblastic/hypochromic anemia)
232127_at CLCN5 Chloride channel 5 (nephrolithiasis 2, X-linked, Dent disease) 0.626 33
218124_at RetSat all-trans-13,14-dihydroretinol saturase 0.63 67
Protein synthesis and degradation
240146_at CAPZA2 Capping protein (actin filament) muscle Z-line, alpha 2 0.267 28
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Table 2. Continuation
235138_at PUM2 Vacuolar protein sorting 35 (yeast) 0.287 25
1560926_at PPP4R2 Protein phosphatase 4, regulatory subunit 2 0.323 88
1554638_at ZFYVE16 zinc finger, FYVE domain containing 16 0.43 56
238303_at SIMP Source of immunodominant MHC-associated peptides 0.432 35
232216_at YME1L1 YME1-like 1 (S. cerevisiae) 0.443 87
239175_at AFTIPHILIN Aftiphilin protein 0.486 4
222499_at MRPS16 mitochondrial ribosomal protein S16 0.537 62
202347_s_at HIP2 huntingtin interacting protein 2 0.565 8
214843_s_at USP33 ubiquitin specific protease 33 0.695 61
Regulation of transcription
1559949_at TRPS1 Trichorhinophalangeal syndrome I 0.199 69
210282_at ZNF198 zinc finger protein 198 0.25 44
202600_s_at NRIP1 nuclear receptor interacting protein 1 0.282 70
243792_x_at PTPN13 Protein tyrosine phosphatase, non-receptor type 13 0.36 43
(APO-1/CD95 (Fas)-associated phosphatase)
222320_at HRPT2 Hyperparathyroidism 2 (with jaw tumor) 0.403 11
222544_s_at WHSC1L1 Wolf-Hirschhorn syndrome candidate 1-like 1 0.408 18
222313_at CNOT2 CCR4-NOT transcription complex, subunit 2 0.412 15
216022_at WNK1 WNK lysine deficient protein kinase 1 0.414 31
235409_at MGA MAX gene associated 0.443 40
212881_at PIAS4 protein inhibitor of activated STAT, 4 0.448 55
227798_at SMAD1 SMAD, mothers against DPP homolog 1 (Drosophila) 0.45 16
213766_x_at GNA11 guanine nucleotide binding protein (G protein), alpha 11 (Gq class)0.487 39
217550_at ATF6 Activating transcription factor 6 0.518 94
222180_at YES1 V-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 0.604 98
218955_at BRF2 BRF2, subunit of RNA polymerase III transcription initiation 0.635 83
factor, BRF1-like
212079_s_at MLL myeloid/lymphoid or mixed-lineage leukemia 0.666 29
(trithorax homolog, Drosophila)
213944_x_at GNA11 guanine nucleotide binding protein (G protein), alpha 11 (Gq class)0.693 59
Other
1559496_at --- --- 0.284 5
234032_at --- PRO1550 0.289 19
242343_x_at ZNF518 Zinc finger protein 518 0.309 68
221543_s_at SPFH2 SPFH domain family, member 2 0.322 6
204148_s_at ZP3 /// zona pellucida glycoprotein 3 (sperm receptor) /// 0.324 65
POMZP3 POM (POM121 homolog, rat) and ZP3 fusion
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Table 2. Continuation
232489_at FLJ10287 hypothetical protein FLJ10287 0.33 1
236841_at FLJ25222 CXYorf1-related protein 0.334 60
227931_at --- MRNA; cDNA DKFZp686D22106 (from clone DKFZp686D22106) 0.382 54
238706_at PAPD4 PAP associated domain containing 4 0.386 63
221542_s_at SPFH2 SPFH domain family, member 2 0.398 24
231878_at MVP Major vault protein 0.412 12
1564637_a_at FLJ38426 hypothetical protein FLJ38426 0.47 52
228971_at --- --- 0.476 95
235970_at MLR1 transcription factor MLR1 0.485 73
230871_at DHX30 DEAH (Asp-Glu-Ala-His) box polypeptide 30 0.5 99
233228_at ZNF407 Zinc finger protein 407 0.508 48
237157_at EVE1 SH3 domain protein D19 0.519 9
215385_at FTO Fatso 0.527 41
222496_s_at FLJ20273 RNA-binding protein 0.528 42
219001_s_at WDR32 WD repeat domain 32 0.533 76
235927_at --- --- 0.542 86
1569813_at STRN striatin, calmodulin binding protein 0.549 66
240939_x_at --- --- 0.557 79
222642_s_at TMEM33 transmembrane protein 33 0.558 81
213984_at SCC-112 SCC-112 protein 0.565 37
234488_s_at GCL /// germ cell-less homolog 1 (Drosophila) 0.619 100
GMCL1L
201297_s_at MOBK1B MOB1, Mps One Binder kinase activator-like 1B (yeast) 0.626 96
238660_at WDFY3 WD repeat and FYVE domain containing 3 0.663 13
212602_at WDFY3 WD repeat and FYVE domain containing 3 0.708 47
212602_at WDFY3 WD repeat and FYVE domain containing 3 0.708 47
Up-regulated in BRCA1(+)
Cell proliferation and death
203139_at DAPK1 death-associated protein kinase 1 1.896 74
209074_s_at TU3A TU3A protein 2.865 89
Cell signalling
227125_at IFNAR2 Interferon (alpha, beta and omega) receptor 2 1.791 23
204613_at PLCG2 phospholipase C, gamma 2 (phosphatidylinositol-specific) 2.083 20
DNA and RNA
203805_s_at FANCA Fanconi anemia, complementation group A /// Fanconi anemia, 2.056 93
complementation group A
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Table 2. Continuation
Immune response
211530_x_at HLA-G HLA-G histocompatibility antigen, class I, G 1.575 38
205067_at IL1B interleukin 1, beta 1.809 78
205671_s_at HLA-DOB major histocompatibility complex, class II, DO beta 2.37 3
206407_s_at CCL13 chemokine (C-C motif) ligand 13 2.89 10
234764_x_at IGLC2 Ig lambda chain V-region (VL-AIG) /// 6.297 51
Immunoglobulin lambda variable 3-21
Metabolism
222046_at ARS2 arsenate resistance protein ARS2 1.475 77
204428_s_at LCAT lecithin-cholesterol acyltransferase 1.767 27
208964_s_at FADS1 fatty acid desaturase 1 1.9 64
1555745_a_at LYZ lysozyme (renal amyloidosis) 7.787 36
Regulation of transcription
221010_s_at SIRT5 sirtuin (silent mating type information regulation 2 homolog) 1.378 32
5 (S. cerevisiae
206090_s_at DISC1 disrupted in schizophrenia 1 1.72 85
Other
237883_at --- Transcribed locus 1.316 84
213938_at CAST CAZ-associated structural protein 1.339 53
1561759_at --- Homo sapiens, clone IMAGE:5276804, mRNA 1.369 50
218600_at MGC10986 hypothetical protein MGC10986 1.46 21
226410_at LOC348180 hypothetical protein LOC348180 1.694 91
241383_at LOC201181 similar to hypothetical protein A930006D11 2.053 34
the expression level of these genes in 12 tumours with
mutations in BRCA1 and 16 tumours without muta-
tion. The results of this analysis were concordant with
the microarray results: both genes seem to be down-
-regulated in BRCA1-linked tumours, when compared
to sporadic ones. The difference in expression level of
TOB1 and SEPHS2 genes in BRCA1-linked tumours
versus BRCA1 negative tumours was statistically signi-
ficant (p-value for TOB1: 0.003, for SEPHS2: 0.005,
Kolmogorov-Smirnov test, Fig. 3).
Discussion
Our preliminary study was done on a relatively
small number of cases; however it may be informati-
ve, as the samples were chosen carefully. In all previo-
us microarray studies on breast cancer it was observed
that the most striking difference in the gene expression
profile is connected with oestrogen receptor status. In-
itially it was stated that ER(+) and ER(-) breast cancers
represent distinct categories of breast tumours [27,
28]. More detailed studies performed on a larger set
of samples revealed further subtypes, e.g. luminal A
and luminal B subtypes among ER(+) tumours and at
least two subtypes: ERBB2+ and ‘basal’ within and
ER(-) group [Perou et al., 2000; Sorlie et al., 2001].
Alternatively, another subdivision of ER(-) cases was
proposed by Farmer at al., who claim two subgroups:
‘basal’, characterized by oestrogen and androgen re-
ceptors negativity and expression of cytokeratins 5 and
17, and ‘molecular apocrine’, negative for ER and po-
sitive for AR [29]. It was also shown previously that
BRCA1 mutation-linked breast cancer tissues cluster
within a ‘basal’ subtype [30]. However, these specific
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cases account only for the minority of ‘basal’ tumo-
urs; thus the genes that are differentially expressed be-
tween basal and other subgroups do not necessarily
reflect a difference in the biology of hereditary (BRCA1-
-linked) and sporadic carcinomas. Moreover, a set of
genes differentiating between breast cancer subtypes
in the studies of Perou and Sorlie was selected from
genes that are stably expressed in the biopsy speci-
mens, taken from the same tumour before and after
chemotherapy. This allowed the construction of so-cal-
led ‘molecular portraits’ of each tumour, but may ha-
ve eliminated some significant genes that could be sup-
pressed by chemotherapy. In our study we analyse on-
ly tumours that have not been subjected to neoadjuvant
chemotherapy. To reduce, at least partially, the sour-
ces of variability that are not linked to BRCA1 status,
we decided to analyse only ER(-) tumour samples. 
The aim of our study was to reveal a set of genes
differentially expressed between BRCA1 mutation-lin-
ked and sporadic breast cancer. Similar study have
been performed by Hedenfalk et al., who analysed
seven sporadic, seven BRCA1- and eight BRCA2-lin-
ked breast cancers and published a set of 51 diffe-
rentially expressed genes. We tried to retrieve infor-
mation about expression of those 51 genes from HG
U133 Plus 2.0 Gene Chip used in our study. Howe-
ver, due to the incompatibility of both types of DNA
microarrays, we were able to find expression data on-
ly for 40 genes (represented by 88 probesets). This
set of genes was unable to discriminate between spo-
radic and hereditary cases from our cohort (not
shown). This may be caused by shortening of the ori-
ginal list of genes and the fact that the set of 51 ge-
nes was selected by comparison of BRCA1 and
BRCA2 tumours with the sporadic ones, all of them
of rather mixed histopathology, grade and ER status.
Of the genes from Hedenfalk’s list only one (TOB1)
is represented, at the 62nd position, in our list of 100
genes selected by limma.
It should be mentioned that Jazaeri et al., who ana-
lysed a cohort of hereditary and sporadic ovarian can-
cers, found by the unsupervised method of data ana-
lysis that BRCA1 and BRCA2 tumours localize separa-
tely from each other, while sporadic cases were placed
by the algorithm between these two groups, some of
them being closer to BRCA1 tumours, others to BRCA2
tumours [31]. This result confirms all previous obse-
rvations that BRCA1 and BRCA2 mutation-linked car-
cinomas are different entities, and suggests that at le-
ast in some sporadic cases BRCA1 or BRCA2 path-
ways may be truncated, thus accounting for BRCA1-like
and BRCA2-like sporadic tumours. It should be veri-
Fig. 2. Hierarchical clustering of samples, based on 100 genes dif-
ferentiating between hereditary and sporadic breast tumors. Colors
on the right bar code for: regulation of transcription (orange), cell
signalling (blue), cell proliferation and death (black), DNA and RNA
replication transcription and processing (red), cellular metabolism
(yellow), protein synthesis and degradation (green), immune respon-
se (violet) and other (grey). It may be seen, that most prominent clu-
ster of genes upregulated in hereditary tumors consists of genes en-
gaged to immune response, what probably reflects lymphocyte in-
filtrate of those tumors
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fied whether this hypothesis applies also to breast can-
cer. Interestingly, in our group of samples Jazaeri’s set
of genes performed better than a set published by He-
denfalk [15] (not shown). 
Prediction of BRCA status in patients with breast
cancer on the basis of clinical and molecular features
would be very useful for genetic counselling and for
cost-reduction of genetic screening [32, 33]. It was
shown recently by Lakhani et al., 2005, that ER status
together with immunochemistry for some markers of
‘basal’ subtype (CK14, CK5/6, CK17 and osteonec-
tin) is better able to predict BRCA1 mutation status in
breast cancer patients than previously used criteria
[34]. Although it must be experimentally proven, we
believe that among 100 genes selected by limma so-
me markers may appear to improve the specificity of
prediction of BRCA1 status.
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